The Allopurinol and Febuxostat in the Treatment of Hyperuricemic Patients and Their Impact on Lipid Fractions (Cholesterol, LDL, HDL)

Mohsin Turab, Syed Saud Hasan, Syeda Amber Zaidi, Shamaila Khalid, Fuad Shaikh, Dabeeran Zehra


Little is known about the role of serum uric acid and its impact on lipid fraction. The associations between hyperuricemia and much co-morbidity such as dyslipidemia and others are well recognized. This study aims to explore the impact of Allopurinol & Febuxostat on the serum lipid levels in hyperuricemia patients. An interventional clinical study was conducted in Medical OPD, Civil Hospital Karachi. The study period was six months, from September 2018 to March 2019. In this clinical trial, after ERC approval, 70 enrolled patients, 60 registered patients of serum uric acid sUA>6.8 mg/dl, after inclusion and exclusion criteria and written consent, detailed history on pro forma and patients were divided into two groups, one to receive allopurinol, 300 mg & second Febuxostat 80 mg, daily for 90-days. Patients' uric acid, cholesterol, LDL, HDL, serum creatinine, alkaline phosphatase, SGOT, and blood sugar for safety profile from baseline, repeated at day 30, 60, and 90, keep in the case record file, on follow-up visits for final analysis. Group-A (Allopurinol treated patients) baseline uric acid was changed from mean 8.79  ±  0.98 to 6.40  ±  0.86, cholesterol 195  ±  30 to 198  ±  31, LDL135  ±  20 to 137  ±  20 & HDL31  ±  07 to 31  ±  06 at day 90. Group-B (Febuxostat treated) sUA mean was 8.85  ±  0.97 to 5.96  ±  0.68, cholesterol 176  ±  36 to 164  ±  25, LDL 129  ±  09 to 124  ±  09, HDL 29  ±  06 to 36  ±  06.  Mean difference  ± SD change in group A & B of sUA 2.39  ±  1.15 & 2.90  ±  0.87, cholesterol - 2.90  ±  4.10 & 12.43  ±  20.76 with p-value < 0.001, LDL - 2.53  ±  6.97 & 4.63  ±  5.05 with p-value < 0.001, HDL 0.20  ±  05.87 & -7.50  ±  2.58 with p-value < 0.001. Febuxostat lowers sUA and reduces cholesterol & LDL but increases HDL, while allopurinol does not impact lipid fractions. Urate lowering drugs interventions change the risk factors and offer a practical and cheap approach to hyperlipidemia and reduce cardiovascular risk.


Keywords: allopurinol, febuxostat, serum uric acid, serum cholesterol, low-density lipoprotein, high-density lipoprotein.


Full Text:



ACEVEDO A., BENAVIDES J., CHOWDHURY M., LOPEZ M., PENA L, MONTENEGRO A., LIEVANO M., and LOMBO B. Hyperuricemia and Cardiovascular Disease in Patients with Hypertension. Connecticut Medicine, 2016, 80(2): 85-90.

ZOU H., WANG H., LIU T., LI X., ZHU X., and WANG Z. Protective role of α-lipoic acid in hyperuricemia induced endothelial dysfunction. Experimental and Therapeutic Medicine, 2017, 13: 3047-3054.

ABBASIAN M., EBRAHIMI H., DELVARIANZADEH M., NOROUZI P., and FAZLI M. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes and Metabolic Syndrome, 2016, 10(3): 32.

LI L.X., DONG X.H., LI M.F., ZHANG R., LI, T.T., SHEN J., BAO Y.-Q., and JIA W.-P. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese in patients with type 2 diabetes. Journal of Hypertension, 2015, 33: 482.

KUWABARA M., HISATOME I., NIWA K., HARA S., RONCAL-JIMENEZ C.A., BJORNSTAD P., NAKAGAWA T., ANDRES-HERNANDO A., SATO Y., JENSEN T., GARCIA G., RODRIGUEZ-ITURBE B., OHNO M., LANASPA M.A., and JOHNSON R.J. Uric Acid Is a Strong Risk Marker for Developing Hypertension from Prehypertension: A 5-Year Japanese Cohort Study. Hypertension, 2018, 71(1): 78-86.

HAO Y., LI H., CAO Y., CHEN Y., LEI M., ZHANG T., XIAO Y., CHU B.Y., and QIAN Z.Y. Uricase and Horseradish Peroxidase Hybrid CaHPO4 Nano flower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. Journal of Biomedical Nanotechnology, 2019, 15(5): 951-965.

HOSOYA T., and NISHIO S. Asymptomatic hyperuricemia. Journal of General and Family Medicine, 2016, 17: 71-76.

EL DIN U.A.A.S., SALEM M.M., and ABDULAZIM D.O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. Journal of Advanced Research, 2017, 8(5): 537-548.

STAMP L., and DALBETH N. Urate-lowering therapy for asymptomatic hyperuricemia: a need for caution. Seminars in Arthritis and Rheumatism, 2017, 46: 457-464.

ALI N., PERVEEN R., RAHMAN S., MAHMOOD S., RAHMAN S., ISLAM S., HAQUE T., SUMON A.H., KATHAK R.R., MOLLA N.H., ISLAM F., MOHANTO N.C., NURUNNABI S.M., AHMED S., and RAHMAN M. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. Plos One, 13: e0206850.

QU L.H., JIANG H., and CHEN J.H. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of Medicine, 2017, 49: 142-156.

WHITE W.B., SAAG K.G., BECKER M.A., BORER J.S., GORELICK P.B., WHELTON A., HUNT B., CASTILLO M., and GUNAWARDHANA L. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 2018, 378(13): 1200-1210.

ROBINSON P.C., and DALBETH N. Febuxostat for the treatment of hyperuricemia in gout. Expert Opinion on Pharmacotherapy, 2018, 19(11): 1289-1299.

RICHETTE P., DOHERTY M., PASCUAL E., BARSKOVA V., BECCE F., CASTANEDA-SANABRIA J., COYFISH M., GUILLO S., JANSEN T.L., JANSSENS H., LIOTÉ F., MALLEN C., NUKI G., PEREZ-RUIZ F., PIMENTAO J., PUNZI L., PYWELL T., SO A., TAUSCHE A.K., UHLIG T., ZAVADA J., ZHANG W., TUBACH F., and BARDIN T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 2017, 76: 29-42.

CHEN C., LÜ J.M., and YAO Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Medical Science Monitor, 2016, 22: 2501-2512.

BORGHI C., and CICERO A.F.G. Serum Uric Acid and Cardiometabolic Disease. Hypertension, 2017, 69 (6): 1011-1013.

KUWABARA M. Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: Population-Based Cohort Study. Circulation, 2019, 139: 1348-1349.

LIN J.D., CHIOU W.K., CHANG H.Y., LIU F.H., and WENG H.F. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism, 2007, 56(6): 751-756.

BALASUBRAMANIAN T. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. Scientific World Journal, 2003, 3: 930-936.

CHENA S., YANGA H., CHENA Y., WANG J., XU L., MIAOC M., and XU C. Association between serum uric acid levels and dyslipidemia in Chinese adults. Medicine, 2020, 99: 11.

ZIGA-SMAJIC N., SKRBO S., OMEROVIC N., DURIC K., DEDIC M., TRNKA A.H., PEHLIVANOVIC B., LAGUMDZIJA D., and BECIC F. Specifics of Treatment of Hyperuricemia with Febuxostat and Its Effects on Concentrations of Total, LDL and HDL Cholesterol, Compared to the Conventional Treatment with Allopurinol. Journal of Pharmaceutical Research International, 2020, 32(35): 44-54.

DE CASTROA V.M.F., DE MELOB A.C., BELOC V.S., and CHAVESA V.E. Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis. Clinical Biochemistry, 2017, 50: 1289-1297.

SARMAH D., and SHARMA B. A correlative study of uric acid with lipid profile. Asian Journal of Medical Sciences, 2013, 4: 8-14.

HEIKAL M.M., SHAABAN A.A., ELKASHEF W.F., and IBRAHIM T.M. Effect of Febuxostat on biochemical parameters of hyperlipidemia induced by a high-fat diet in rabbits. Canadian Journal of Physiology and Pharmacology, 2019, 97(7): 611-622.

LIN J.D., CHIOU W.K., CHANG H.Y., LIU F.H., and WENG H.F. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism, 2007, 56(6): 751-756.


  • There are currently no refbacks.